Literature DB >> 31387379

The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis.

Hiroshi Ishii1, Yoshiaki Kinoshita2, Hisako Kushima3, Nobuhiko Nagata1, Kentaro Watanabe4.   

Abstract

The idiopathic form of pleuroparenchymal fibroelastosis (PPFE) is categorized as a rare idiopathic interstitial pneumonia in the current classification. The majority of PPFE cases are idiopathic, but many predisposing factors or comorbidities have been reported. Although histological PPFE is predominantly located in the upper lobes, which are less often affected by fibrosis in patients with idiopathic pulmonary fibrosis (IPF), the clinical course of PPFE is seemingly similar to that of IPF. However, upper lobe fibroelastosis has various clinical and physiological characteristics that differ from those of IPF, including a flattened thoracic cage and a marked decrease in the forced vital capacity (FVC) but with a preserved residual volume. Compared with IPF, the decrease in the walking distance is mild despite the markedly decreased FVC in PPFE, and chest radiograph more frequently shows the elevation of bilateral hilar opacities with or without tracheal deviation. The prognosis may be related to the development of fibrosing interstitial pneumonia in the lower lobes with elevated levels of serum Krebs von den Lungen-6; however, there is marked variation in the pathogenesis and clinical features in PPFE. A proposal of the diagnostic criteria for idiopathic PPFE with and without surgical lung biopsy, which has recently been published, may be useful.

Entities:  

Keywords:  Pleuroparenchymal fibroelastosis; clinical difference; clinical similarity; diagnostic criteria; idiopathic pulmonary fibrosis

Year:  2019        PMID: 31387379      PMCID: PMC6685112          DOI: 10.1177/1479973119867945

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


Introduction

Pleuroparenchymal fibroelastosis (PPFE) was first reported by Frankel et al.,[1] who described five patients with pulmonary fibrosis predominantly involving the upper lobes. This disease was named according to its unique histology, and the idiopathic form is now listed as a rare idiopathic interstitial pneumonia (IIP) in the classifications of the American Thoracic Society and the European Respiratory Society.[2] Although histological PPFE is predominantly located in the upper lobes, which are less commonly affected by fibrosis in patients with idiopathic pulmonary fibrosis (IPF), the clinical course of PPFE progresses slowly and is similar to that of chronic fibrosing interstitial pneumonias, such as IPF. Since the report by Frankel et al.,[1] an increasing number of studies have examined PPFE and there is increased interest in the clinical similarities and differences between PPFE and IPF. The aim of this review is to evaluate the similarities and differences between PPFE and IPF for further understanding of these diseases. 1. Age of onset: The age at the onset in PPFE patients is wide-ranging (from 20s to 80s) and therefore dissimilar to IPF, which tends to affect older individuals. Young patients are predisposed to develop late-onset transplantation-associated PPFE when they undergo bone marrow transplantation due to hematopoietic disorders (Table 1).
Table 1.

Patient background characteristics.

PPFEIPF
Age of onset, years old20–80 years old>50 years old
GenderMale = femaleMale > female
Genetic factorOccasionalNot rare
Medical history, comorbidityRecurrent respiratory infections,a treatment for malignancies, organ transplantationsb No specific diseases
PneumothoraxFrequentOccasional
Autoimmune diseases, autoantibodiesRheumatoid arthritis, microscopic polyangiitis, ulcerative colitis, etc.(Occasionally) rheumatoid factor, antinuclear antibody
Dust exposureAsbestos, etc.None
Smoking historyAbout 30%>50%

PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis.

a Nontuberculous mycobacteriosis, aspergillosis, etc.

b Chemotherapy, radiotherapy.

2. Gender: Although more men are affected by IPF than women, there is no gender preponderance in PPFE. However, the number of reports on PPFE is relatively smaller at present than that of reports on IPF. 3. Genetic factor: Some investigators have reported PPFE in siblings[1,3,4] and a pair of parents and their child,[4] and PPFE with a family history of other pulmonary fibrosis has also been reported.[5,6] Hereditary disposition may be responsible for the age at the onset in some patients with PPFE. IPF is idiopathic by definition. However, genetic factors may not be rare in IPF,[7,8] because a part of IPF cases are familial and even more present either hereditary or sporadic genetic mutations which seem to play a major role in the pathogenesis of the disease.[9,10] 4. Medical history and comorbidities: Compared with IPF, throughout its long clinical course, PPFE patients can develop recurrent respiratory infections with progressive contraction of upper lobes. Although Aspergillus infection and Mycobacterium infection have been reported as causes of infection-related PPFE,[6,11,12] whether the PPFE-like lesions are induced by these infections or latent PPFE creates suitable developmental conditions for these infectious agents is unclear. Respiratory infections, such as aspergillosis as an opportunistic infection, are also observed in the end stage of IPF.

The similarities and differences between PPFE and IPF

Clinical background characteristics

It is well-known that PPFE can occur after bone marrow[6,13,14] or lung transplantation,[15,16] probably due to the chronic phase of graft-versus-host disease, administered alkylating agents, or chronic rejection. PPFE might be a special form of radiation injury, extending to nonirradiated areas to form irreversible pulmonary fibrosis. Hamada et al. reported a patient with cyclophosphamide-induced pulmonary fibrosis and elastosis with pleural thickening after treatment for breast cancer.[17] 5. Pneumothorax: Compared with IPF, many patients with PPFE experience recurrent pneumothorax. Multiple bullae in the upper lobe of the lung that appear in the course of the disease may be torn and cause recurrent pneumothorax. 6. Autoimmune diseases and autoantibodies: Although IPF is idiopathic, ankylosing spondylitis,[18] ulcerative colitis,[19] and psoriasis[20] were previously reported as underlying diseases in PPFE. Pulmonary upper lobe fibrosis and cavitation in patients with rheumatoid diseases have also been reported.[21] Pleuroparenchymal disease in collagen vascular disease might share common histological features with PPFE. Some reports[1,6,22] have described positivity for rheumatoid factor and antinuclear antibody in patients with PPFE, suggesting the role of autoimmune mechanisms in the pathogenesis of the disease in some patients. Enomoto et al. reported that radiologic PPFE-like lesion in patients with connective tissue disease-related interstitial lung disease was not uncommon and was associated with poor prognosis.[23] In addition, we showed in a recent report[24] that a histological PPFE pattern was found in 12 of 24 patients with autoimmune disease-related interstitial lung disease (50%), and a histological PPFE pattern as the dominant pattern of fibrosis was found in 2 of the 24 patients (8%). 7. Dust exposure: Although IPF is idiopathic, occupational exposure to certain types of dust, such as asbestos or aluminum, is an important factor that induces PPFE.[13,25-28] In general, pneumoconiosis, such as asbestosis, silicosis, and berylliosis, may present as upper lobe fibrosis, although the PPFE pattern has not been histologically demonstrated in these pneumoconioses. As the interstitial connective tissue response in asbestosis is fibroelastotic rather than fibrotic,[29] with pleural thickening, asbestos exposure might directly induce the pathology of PPFE. 8. Smoking history: Smoking does not appear to have any effect on the occurrence of PPFE. Previous studies[1,4,6,11,13,20,22,25,27,28,30-34] indicated that the rate of current and former smokers was approximately 30% among PPFE patients and was over 50% among IPF patients, showing a marked difference between PPFE and IPF. Patient background characteristics. PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis. a Nontuberculous mycobacteriosis, aspergillosis, etc. b Chemotherapy, radiotherapy. 1. Clinical symptoms: Most patients with both PPFE and IPF present with a slow onset. However, the clinical characteristics should be separately discussed in idiopathic and secondary forms of PPFE. A considerable number of patients with PPFE have underlying diseases or conditions that might be relevant to its occurrence and development. The main symptoms in patients with PPFE and IPF are dry cough and exertional dyspnea. Such symptoms appear insidiously. Chest pain due to pneumothorax may be the first symptom in some patients with PPFE. Many patients with PPFE complain of weight loss (Table 2).
Table 2.

Clinical and laboratory findings.

PPFEIPF
Pattern of onsetSlowlySlowly
Early symptomExertional dyspnea, dry cough, chest painExertional dyspnea, dry cough
EmaciationNoticeableModest
Flat chestNoticeable, progressiveNone
Finger clubbingRareFrequent
Fine cracklesAbout half casesMost cases
Serum KL-6Normal to slightly elevatedElevated
Serum SP-DElevatedElevated
Serum SP-ANormal or elevatedNormal or elevated

PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; KL-6: Krebs von den lungen-6; SP: surfactant protein.

2. Physical findings: Compared with IPF, patients with PPFE are often associated with a slender stature.[3,4,11,30,32,35] “Flattened thoracic cage” is also a characteristic physical finding in PPFE.[3,33,36] A flattened thoracic cage is observed in patients with not only idiopathic PPFE but also secondary PPFE. A flattened thoracic cage, which may result from a congenital disposition or may be a secondary change of the thorax due to the shrinkage of the upper lung lobes through the long process of fibrosis, may inhibit the compliance of the lungs and the blood flow in the upper lobes, leading to a ventilation-perfusion imbalance.

Clinical and laboratory findings

Finger clubbing, which is often seen in patients with IPF, has been rarely reported in patients with PPFE.[33,37] A number of case studies of PPFE have reported that crackles are audible in about half or less than half of patients,[1,6,11,14,25-28,30-33,35,38] indicating that crackles are audible less frequently in PPFE than in IPF. 3. Laboratory findings: Krebs von den Lungen-6 (KL-6) is a reliable serum marker that is used for the diagnosis of interstitial lung diseases,[39-41] such as IPF. Our recent report[42] suggests that pulmonologists should be aware that the time course of the serum KL-6 levels in untreated patients with IPF is heterogeneous and can naturally decline in association with disease progression. Serum KL-6 is usually within the normal range or around the upper normal range limit in patients with PPFE.[6,22,26,27,31-33,43] Histologically, PPFE is a fibrotic lung disease, but it is not an interstitial pneumonia, such as usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), in which KL-6 is highly expressed in the regenerated type II pneumocytes, migrating into the bloodstream.[41] However, as the disease progresses, the level tends to increase in PPFE.[11,43,44] UIP-like lesions may contribute to the increase in the serum levels of KL-6. We have reported that an elevated level of serum KL-6 was suggestive of a poor prognosis for patients with PPFE and that lower lung lesions were more frequently observed in nonsurvivors than in survivors of PPFE.[33] Serum surfactant protein D (SP-D) may be elevated in PPFE.[22,33,37,43] Clinical and laboratory findings. PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; KL-6: Krebs von den lungen-6; SP: surfactant protein. 1. Pulmonary function test: In both PPFE and IPF, forced vital capacity (FVC) and total lung capacity (TLC) are decreased, but the ratio of the forced expiratory volume in 1 second (FEV1)/FVC is increased. Fibrotic collapse of the upper lobes leads to the compensatory overinflation of the lower lobes, resulting in an increased ratio of residual volume (RV)/TLC in PPFE,[16,22,33,43] which is a characteristic functional impairment that is not usually seen in IPF. We showed that the RV/TLC ratio was significantly correlated with the gender, age and physiological variables (GAP) scores and negatively correlated with the FVC and body mass index (BMI).[33] This strongly suggests that the RV/TLC ratio increases with the progression of the disease and emaciation. We also demonstrated that such functional abnormalities seemed to be related to the deformity of chest cage, that is, as the thoracic cage becomes flattened, the FVC decreases, but the RV/TLC increases (Table 3).[33,36]
Table 3.

Pulmonary function test findings.

PPFEIPF
SpirometryFVCDecreaseDecrease
FEV1/FVC (%)IncreaseIncrease
Lung volume fractionTLCDecreaseDecrease
RV/TLC (%)IncreaseImmutable to decrease
Gas exchange capacityDLcoDecreaseDecrease
Six-minute walk distanceDecreaseMarked decrease

PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; TLC: total lung capacity; RV: residual volume; DLco: diffusing capacity for carbon monoxide.

Physiology

Gas exchange impairment also appears as a restrictive impairment. The diffusing capacity of carbon monoxide (DLco) is decreased. However, the diffusing capacity is normal or minimally reduced when DLco is divided by alveolar volume (DLco/VA).[37] 2. Six-minute walk distance: Compared with the results for IPF reported by other investigators,[45-47] the decrease in walking distance was mild despite the markedly decreased FVC.[33] Similarly, the lowest SpO2 did not fall as extensively as it does in cases of IPF. Preserved alveolar structures in PPFE might be partly responsible for minimizing the decreased walking distance and SpO2 during exercise. Furthermore, a slender body build might also contribute to the preservation of the walking capacity.[48] Pulmonary function test findings. PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; TLC: total lung capacity; RV: residual volume; DLco: diffusing capacity for carbon monoxide. 1. Chest radiograph: In contrast to IPF, wherein lower lung field predominance reticular opacities are observed, irregularly thickened apical parts and reticular opacities appear in the bilateral upper lung fields in PPFE. Such a finding may be incidentally observed in a medical checkup for PPFE patients. Later, chest radiograph (Figure 1) more frequently shows the elevation of bilateral hilar opacities compared with IPF, with or without tracheal deviation.[49] A lateral view demonstrates an abnormally narrowed anterior–posterior thoracic dimension due to a flattened thoracic cage in PPFE (Table 4).
Figure 1.

Representative chest radiograph of a PPFE patient (56-year-old woman) showing reticular opacities in the bilateral upper lung fields and the elevation of bilateral hilar opacities with a rightward deviation of the trachea. PPFE: pleuroparenchymal fibroelastosis.

Table 4.

Chest imaging findings.

PPFEIPF
DistributionUpper field predominanceLower field predominance
Upward shift of hilar structuresFrequentNone to occasional
Tracheal deviationFrequentSometimes
HRCT pattern
 Upper lung fieldMultiple subpleural areas of airspace consolidation with traction bronchiectasisNone or nonspecific change
 Lower lung fieldNone, PPFE, or other patternsUIP pattern or probable UIP pattern

PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia.

2. Chest computed tomography (CT): In patients with IPF, lower lung lobe and peripheral area predominance UIP pattern or probable UIP pattern[50] are observed. In patients with PPFE, multiple subpleural areas of airspace consolidation with traction bronchiectasis, subpleural nodular or reticular opacities in the lung parenchyma are found in upper lung lobes bilaterally, but changes in the middle and lower lobes are minimal (Figure 2). In the early phases of PPFE, the disease may be not distinguishable from pulmonary apical cap or fibroelastic scar in high-resolution computed tomography (HRCT). A follow-up imaging is therefore pivotal in these patients. As the disease progresses, the opacities described above extend to the adjacent lobes. At the advanced stage of PPFE, fibrotic shadows extend to the lower lung fields, and the diaphragm is elevated with the loss of the bilateral lung volume. Multiple bullae and cystic lesion often appear in the upper lung fields, which may be responsible for pneumothorax and allow Aspergillus infection. Isolated reticular opacities or honeycombing sometimes appear in the subpleural areas of lower lobes, which raises the possibility of the combination of PPFE with other patterns of interstitial pneumonia.[6,11,16,33]
Figure 2.

Representative chest CT scans of a PPFE patient (45-year-old man) showing subpleural airspace consolidation and reticular opacities predominantly in the upper lung lobes. PPFE: pleuroparenchymal fibroelastosis; CT: computed tomography.

Representative chest radiograph of a PPFE patient (56-year-old woman) showing reticular opacities in the bilateral upper lung fields and the elevation of bilateral hilar opacities with a rightward deviation of the trachea. PPFE: pleuroparenchymal fibroelastosis. Chest imaging findings. PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia. Representative chest CT scans of a PPFE patient (45-year-old man) showing subpleural airspace consolidation and reticular opacities predominantly in the upper lung lobes. PPFE: pleuroparenchymal fibroelastosis; CT: computed tomography.

Histology

PPFE is histologically characterized by subpleural fibrosis with a mixture of elastic tissue and dense collagen but without the architectural distortion frequently seen in IPF.[1] In other words, mainly in the upper lobes, there is alveolar collapse with subpleural atelectatic induration and the proliferation of elastosis and intraluminal organization or intra-alveolar fibrosis with or without fibrously thickened pleura. Such pathological features of PPFE are totally different from those of IPF. However, the histology patterns in the lower lobes range from PPFE, UIP, to histologically unclassifiable interstitial pneumonia.[33] In addition, our recent work has demonstrated that IPF occasionally shows intense elastosis in the upper lobes, based on whole-slide image analysis using the specimens of autopsy or pneumonectomy for lung transplantation.[51] Such cases are histologically indistinguishable from PPFE, suggesting that there may be histologically borderline cases of PPFE and IPF (Table 5).
Table 5.

Histological findings.

PPFEIPF
DistributionUpper field predominanceLower field predominance
Histological patternSubpleural fibrosis with a mixture of elastic tissue and dense collagen, with/without UIP or other patterns of pulmonary fibrosisUIP pattern
Lung architectureIntact architectureArchitectural distortion
Old fibrosisSeptal elastosis and intra-alveolar collagenous fibersFibrotic scar and honeycombing consisting of collagenous fibers
Fibroblastic focusNone or minorMajor
Pleural lesionNone or thickeningNone

PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; UIP: usual interstitial pneumonia.

Histological findings. PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; UIP: usual interstitial pneumonia. PPFE patterns are identified in the upper lungs without difficulty on both CT images and in histology specimens; in contrast, the lower lungs have complicated imaging findings and histology patterns. In the lower lungs, there are borderline patterns difficult to classify as simply UIP or PPFE on CT and histology specimens.[51] Based on our observations over the years, we suspect that the progression of PPFE in the lower lungs largely depends on newly developed chronic fibrosing IP, UIP, or non-UIP, rather than on the progression of histological PPFE itself. As shown in Table 5, the distinctive trait of UIP is the fibroblastic focus with destructive fibrosis which is absent in PPFE. It would be interesting to search for these characteristics in the lower lobe fibrosis in patient with upper lobe fibrosis consistent with PPFE. It is probable that a rapid progression actually caused by a UIP in the lower lobe, therefore reducing the weight of PPFE.

Treatment and the prognosis

Idiopathic PPFE is usually slowly progressive and refractory to steroids or immunosuppressive agents. Antifibrotic agents for IPF, such as pirfenidone and nintedanib, seem useless or do not meet the indication of PPFE. In the advanced stage of PPFE, home oxygen therapy is necessary if the patient is hypoxemic, and infection control is important, as in IPF. Targeting the inhibition of elastosis instead of collagenosis might represent a novel therapeutic avenue in PPFE. Previous reports found the median survival of patients with PPFE to be 7.3–11 years.[16,33] This seems to be longer than that of IPF in Japan.[52] However, disease progression of PPFE is highly variable: some patients show rapid progression,[11] while others have slow progression of 10–20 years following clinical presentation.[3,16] This might be caused by the varying underlying conditions or comorbidities or by coexisting fibrosing IP.

Conclusion

The clinical course of PPFE is seemingly similar to that of IPF. However, the clinical and physiological characteristics of upper lobe fibroelastosis differ from those of IPF, including a flattened thoracic cage and a marked decrease in the FVC but with a preserved RV. Compared with IPF patients, finger clubbing is uncommon and the decrease in the walking distance is mild despite the markedly decreased FVC in PPFE patients. The prognosis may be related to the development of fibrosing interstitial pneumonia in the lower lobes; however, there is marked variation in the pathogenesis and clinical features of PPFE. The diagnostic criteria for IPF have been recently updated,[50] and cases presenting with typical UIP pattern on HRCT can be clinically diagnosed without a surgical lung biopsy (SLB). Although the current diagnostic criteria for PPFE are based on the histological findings by an SLB, we have few chances to perform an SLB for the diagnosis of PPFE. Our proposal concerning the criteria for the diagnosis of idiopathic PPFE with and without an SLB has recently been published.[53] Imaging criteria and physiological criteria using the RV/TLC and BMI are expected to be useful for discriminating idiopathic PPFE from a group of chronic IIPs when an SLB cannot be performed.
  52 in total

1.  Idiopathic progressive pulmonary fibrosis.

Authors:  D Davies; J S Crowther; A MacFarlane
Journal:  Thorax       Date:  1975-06       Impact factor: 9.139

2.  [Case of idiopathic pulmonary upper lobe fibrosis].

Authors:  Akie Morimoto; Yoshirou Mochizuki; Yasuharu Nakahara; Tetsuji Kawamura; Shin Sakaki; Youichirou Kobashi
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2010-12

Review 3.  Smoking-related interstitial lung diseases: a concise review.

Authors:  J H Ryu; T V Colby; T E Hartman; R Vassallo
Journal:  Eur Respir J       Date:  2001-01       Impact factor: 16.671

4.  [Idiopathic pulmonary fibrosis of the upper lobe: a case report].

Authors:  Y Kobayashi; M Sakurai; M Kushiya; T Mizukoshi; Y Nishi; J H Choo; M Shibasaki; K Tabe; K Sakata; M Nagata; K Kuramitsu; Y Sakamoto; K Kaneko; H Shimizu; Y Kawabata
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  1999-10

5.  Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia.

Authors:  Tam Eaton; Pam Young; David Milne; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2005-01-07       Impact factor: 21.405

6.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Authors:  William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

7.  Reference equations for the six-minute walk in healthy adults.

Authors:  P L Enright; D L Sherrill
Journal:  Am J Respir Crit Care Med       Date:  1998-11       Impact factor: 21.405

8.  Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis.

Authors:  A Yokoyama; N Kohno; H Hamada; M Sakatani; E Ueda; K Kondo; Y Hirasawa; K Hiwada
Journal:  Am J Respir Crit Care Med       Date:  1998-11       Impact factor: 21.405

9.  Pleuroparenchymal Fibroelastosis: Its Clinical Characteristics.

Authors:  Kentaro Watanabe
Journal:  Curr Respir Med Rev       Date:  2013-06

10.  Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease.

Authors:  Yasunori Enomoto; Yutaro Nakamura; Thomas V Colby; Takeshi Johkoh; Hiromitsu Sumikawa; Koji Nishimoto; Katsuhiro Yoshimura; Sayomi Matsushima; Yoshiyuki Oyama; Hironao Hozumi; Masato Kono; Tomoyuki Fujisawa; Noriyuki Enomoto; Naoki Inui; Toshihide Iwashita; Takafumi Suda
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

View more
  2 in total

Review 1.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

2.  Physiological Criteria Are Useful for the Diagnosis of Idiopathic Pleuroparenchymal Fibroelastosis.

Authors:  Takato Ikeda; Yoshiaki Kinoshita; Yusuke Ueda; Tomoya Sasaki; Hisako Kushima; Hiroshi Ishii
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.